Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07787117 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07787117 · ClinicalTrials.gov record · last posted 2026-08-26

QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol

Name: QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol — clinical trial record (NCT07787117)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: QUARTZ

StatusNot Yet Recruiting

PhaseNot specified

SponsorAstraZeneca

Started2026-08-03

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The QUARTZ study is a retrospective observational cohort study using a prevalent new-user design and U.S. healthcare claims data to evaluate treatment effectiveness among patients with asthma. The study compares the real-world effectiveness of switching from albuterol-only rescue therapy to albuterol/budesonide versus adding low-dose inhaled corticosteroids (ICS) or leukotriene receptor antagonists (LTRA) while continuing albuterol. The primary objective is to assess the comparative effectiveness of these treatment strategies in reducing severe asthma exacerbations in routine clinical practice in the United States.

Trial Details

NCT Number	NCT07787117
Lead Sponsor	AstraZeneca
Conditions	Asthma
Enrollment	2,669 participants
Start Date	2026-08-03
Primary Completion	2026-09-30 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-26